Results 71 to 80 of about 20,527 (318)
Drug Design, Development and Therapy, 2023 Sarah Balboul,1 Julia Kahn,1 Alexis Tracy,2 Anjelica Peacock,3 Abigail Cline2– 4 1School of Medicine, New York Medical College, Valhalla, NY, USA; 2Department of Dermatology, New York Medical College, Valhalla, NY, USA; 3Department of Dermatology ...
Balboul S +4 more
doaj
Research highlights from the 2018 European Respiratory Society International Congress: Airway disease [PDF]
, 2010 The annual European Respiratory Society (ERS) International Congress (held in Paris in 2018) was once again a platform for discussion of the highest-quality scientific research, cutting-edge techniques and innovative new therapies within the respiratory ...
Andersson, Cecilia +6 more
core +1 more source
Successful Treatment of Dupilumab in Two Cases of Refractory Kimura's Disease
JEADV Clinical Practice, EarlyView.ABSTRACT Kimura disease (KD) is a chronic inflammatory disorder characterized by subcutaneous nodules, cervical lymphadenopathy, hypereosinophilia, and elevated IgE levels. Treatment options are limited. We report two cases of refractory KD successfully treated with dupilumab.
Manon Blaise +6 more
wiley +1 more source
Infections in Dupilumab Clinical Trials in Atopic Dermatitis : A Comprehensive Pooled Analysis [PDF]
, 2019 Background: Patients with moderate-to-severe atopic dermatitis (AD) have increased infection risk, including skin infections and systemic infections. Immunomodulators (e.g., anti-tumor necrosis factors, anti-interleukin [anti-IL]-23, anti-IL-17, Janus ...
Akinlade, B. +16 more
core +1 more source
Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis. [PDF]
, 2020 Eosinophilic esophagitis (EoE) is an allergen-mediated inflammatory disease with no approved treatment in the United States. Dupilumab, a VelocImmune-derived human monoclonal antibody against the interleukin (IL) 4 receptor, inhibits IL4 and IL13 ...
Akinlade, B. +20 more
core +1 more source
JEADV Clinical Practice, EarlyView.ABSTRACT We present the case of a 79‐year‐old female patient diagnosed with psoriasis who developed paradoxical drug reactions after administration of anti‐IL17 and anti‐IL‐23 inhibitors. Having shifted towards a rather eczematous phenotype, the patient received an anti‐IL‐4/IL‐3 inhibitor, subsequently developing erythroderma.
Tugce Guel +4 more
wiley +1 more source
Life, 2022 Dupilumab is the only available biological treatment for moderate-to-severe atopic dermatitis (AD). Even so, limited clinical data regarding its safety profile are available.
George G. Mitroi +6 more
doaj +1 more source
COLLAB: A Global Survey of Clinical and Laboratory Assessment in Alopecia Areata by Hair Specialists
JEADV Clinical Practice, EarlyView.ABSTRACT Background Alopecia areata (AA) is a common non‐scarring alopecia. Data continue to emerge on associations with autoimmune and other conditions. Janus kinase inhibitors (JAKi) are increasingly used to treat AA. Objectives The aim was to assess variation in laboratory testing in patients with AA among hair experts internationally and to compare
Cathal O'Connor +39 more
wiley +1 more source
International Journal of Women's Dermatology, 2019 Background: The mechanisms underlying eye-related complications with dupilumab are poorly understood. Objective: This study aimed to determine the incidence and characteristics of ocular complications with dupilumab and the prevalence of comorbid ...
Jodie Raffi, BA +4 more
doaj
Management of dupilumab-associated ocular surface diseases in atopic dermatitis patients
Swiss Medical Weekly, 2021 Atopic dermatitis is a chronic inflammatory skin disease characterised by eczematous skin lesions and intense pruritus. It is often associated with other atopic diseases such as allergic rhinitis and conjunctivitis, bronchial asthma and eosinophilic ...
Yan Guex-Crosier +8 more
doaj +1 more source